News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Jan 03, 2023
Mr. Staggs elevated from "interim" to "permanent" CEO as SWK advances multiple initiatives in 2023 Ms. Dotter joined SWK's Board of Directors in February 2022 DALLAS, Jan. 3, 2023 /PRNewswire/ --...
- Nov 16, 2022
SW K Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, announced the...
- Nov 09, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET Corporate Highlights Successful leadership transition with Jody Staggs named President and...
- Nov 08, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, November 10, 2022, at 10:00 a.m. ET DALLAS, Nov. 8, 2022 /PRNewswire/ -- SWK Holdings Corporation (NASDAQ: SWKH) ("SWK" or the...
- Oct 26, 2022
Oral Presentation Delivered at the American Society for Reproductive Medicine Scientific (ASRM) 2022 Congress & Expo BOONTON, N.J., Oct. 26, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...
- Oct 18, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...
- Oct 10, 2022
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Oct 03, 2022
Yvette Heinrichson promoted to Chief Financial Officer John David Tamas promoted to Director of Underwriting DALLAS, Oct. 3, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or...
- Sep 12, 2022
Physicochemical properties of peptides can provide key insights to potential success of oral delivery BOONTON, N.J., Sept. 12, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a biotechnology company...
- Sep 07, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...
- Sep 01, 2022
Jody Staggs appointed as President and Interim CEO CEO Winston Black will assist in an interim consulting role after successfully establishing SWK Holdings as a leading life science focused...
- Aug 10, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET Corporate Highlights Celebrated 10th anniversary as a life science focused specialty finance...
- Aug 09, 2022
Conference Call and Live Audio Webcast Scheduled for Thursday, August 11, 2022, at 10:00 a.m. ET DALLAS, Aug. 9, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...
- Aug 03, 2022
Article describes Enteris' strengths and scalability in working with highly potent active pharmaceutical ingredients BOONTON, N.J., August 3, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...
- Jul 14, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jul 13, 2022
Since 2012, SWK Holdings has completed financings with 46 life sciences companies, deploying $650 million of capital Second Quarter 2022 Financial Results to be Announced in August DALLAS, July...
- Jun 27, 2022
SWK Holdings Corporation (Nasdaq: SWKH), a life science-focused specialty finance company catering to small-and mid-sized commercial-stage companies, announced today its addition to the Russell...
- Jun 13, 2022
Data suggest that oral formulations of leuprolide developed utilizing Enteris' Peptelligence® platform successfully deliver meaningful circulating drug concentrations and achieve hormonal...
- Jun 07, 2022
Facilities and processes key to protecting workers and the environment, the paper in Drug Development & Delivery says BOONTON, N.J., June 7, 2022 /PRNewswire/ -- Enteris BioPharma, Inc., a...
- May 26, 2022
Enteris BioPharma, Inc. gave plush animals a dose of personality as they created a dozen stuffed teddy bears for Ronald McDonald House Charities to help comfort sick children as they undergo...
- May 19, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, announced today that...
- May 11, 2022
In the news release, SWK Holdings Corporation Announces Financial Results for First Quarter 2022, issued 11-May-2022 by SWK Holdings Corporation over PR Newswire, we are advised by the company...
- May 10, 2022
Conference Call and Live Audio Webcast Scheduled for Wednesday, May 11, 2022, at 10:00 a.m. ET DALLAS, May 10, 2022 /PRNewswire/ -- SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the...
- May 04, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Apr 12, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Apr 04, 2022
Article describes unique features of Enteris' Peptelligence® and ProPerma® peptide and small molecule oral delivery technology BOONTON, N.J., April 4, 2022 /PRNewswire/ -- Enteris BioPharma,...
- Mar 28, 2022
Conference Call and Live Audio Webcast Scheduled for Monday, March 28, 2022, at 10:00 a.m. ET Corporate Highlights Reconstituted Board and appointed Wendy DiCicco, Robert K. Hatcher, and Laurie Dotter
- Mar 25, 2022
Advanced Oxygen Therapy Inc. (AOTI), the global leader in noninvasive topical oxygen wound healing solutions, announced today they have closed a significant round of growth funding from the...
- Mar 23, 2022
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...
- Mar 07, 2022
NEWTON, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for...
- Mar 07, 2022Paper examines barriers to achieving optimal content uniformity with HPAPIs and the techniques manufacturers should use with low-dose drug products
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 02, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Feb 16, 2022
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced the reconstitution of the...
- Feb 15, 2022Six feasibility programs underway for oral tablet formulations developed with Enteris' Peptelligence® and ProPerma® technology platforms
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Feb 09, 2022Fourth Quarter 2021 Financial Results to be Announced in March
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...
- Jan 10, 2022
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 05, 2022
SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") today announced that the special committee of the Company's board of directors (the "Special Committee") has concluded its...
- Jan 05, 2022Enteris continues to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma® platforms
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Dec 27, 2021Capital infusion to finance inventory and annual recurring revenue subscriptions replaces expiring debt with more favorable terms
REDWOOD CITY, CA / ACCESSWIRE / December 27, 2021 /Biotricity Inc. (NASDAQ:BTCY) a modern medical technology company delivering innovative, remote biometric monitoring solutions, today announced...
- Dec 20, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Dec 09, 2021Fourth milestone payment triggered by successful completion of process technology transfer related to the development of Oral KORSUVA™
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Nov 24, 2021Announces Formation of Special Committee
SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") confirmed that on November 23, 2021, it received a non-binding proposal from funds managed by Carlson Capital, L.P. ("Carlson") to...
- Nov 17, 2021Paper Discusses the 505(b)(2) Pathway as a Vehicle for Innovation and Product Differentiation
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Nov 12, 2021Conference Call and Live Audio Webcast Scheduled for Monday, November 15, 2021 at 10:00 a.m. ET
Corporate Updates Conclusion of strategic review process with SWK to focus on specialty finance receivables business SWK evaluating ongoing dividend and additional leverage Third Quarter 2021...
- Nov 02, 2021Paper Examines the Opportunities and Challenges in Working with High Potency APIs
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Nov 01, 2021Commitment to focus on and grow SWK's core specialty finance business going forward
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided an...
- Oct 26, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Oct 13, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Oct 04, 2021Data indicates optimized Peptelligence oral leuprolide formulation delivers comparable or greater drug levels than subcutaneous or depot injection
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Aug 23, 2021Enteris recognized for the third consecutive year in Pharmaceutical Company category
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Aug 16, 2021Conference Call and Live Audio Webcast Scheduled for Tuesday, August 17, 2021 at 10:00 a.m. ET
Corporate Updates The Specialty Finance Receivables and Pharmaceutical Development segments each reported strong quarters Closed a $5.0 million synthetic royalty transaction in April 2021 and a...
- Jul 19, 2021Second Quarter 2021 Financial Results to be Announced in August
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an...
- Jun 23, 2021
SWK Holdings Corporation (Nasdaq: SWKH) ("SWK" or the "Company"), a life science focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that...
- Jun 15, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jun 11, 2021Third milestone payment related to the development of Oral KORSUVA™
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Jun 07, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- May 17, 2021Conference Call and Live Audio Webcast Scheduled for Tuesday, May 18, 2021 at 10:00 a.m. ET
Corporate Updates YTD SWK has closed two financings totaling up to $14.0 million Enteris BioPharma subsidiary announced completion of manufacturing facility expansion and launch of CDMO business...
- May 17, 2021
The Board of Directors (the "Board") of SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") and its controlling stockholder, funds affiliated with Carlson Capital, L.P. ("Carlson"),...
- May 03, 2021CDMO Business Driven by Custom Solutions from Bench to Market for the Development and Manufacture of Difficult to Formulate Drugs and Highly Potent Compounds
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Apr 06, 2021
SWK Holdings Corporation (Nasdaq: SWKH) (the "Company" or "SWK") confirmed that on April 5, 2021, a Special Committee (the "Special Committee") of the Company's Board of Directors received a...
- Mar 31, 2021Specialty Finance Portfolio Growth, Underlying Credit Performance Highlight Strong 2020
Corporate Highlights Closed four transactions in 2020 deploying $34.8 million; additional $8.1 million deployed to existing borrowers Income producing assets as of December 31, 2020 reached an...
- Mar 24, 2021
Sincerus Pharmaceuticals, the parent company of Prescriber's Choice and Sincerus Florida, today announced the completion of a major new round of growth financing with SWK Holdings Corporation (Nasdaq:
- Mar 16, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 15, 2021
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that Winston Black, Chairman...
- Feb 16, 2021Specialty Finance Portfolio Growth, Underlying Credit Performance Highlight Strong 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided an update on the progress and...
- Jan 12, 2021
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 07, 2021Enteris poised to capitalize on multiple value building opportunities involving Peptelligence® and ProPerma™ platforms
Rajiv Khosla, Ph.D., named Chief Executive Officer Gary A. Shangold, M.D., appointed Chief Medical Officer Received two milestone payments totaling $5 million from Cara Therapeutics per licensing...
- Jan 04, 2021
Flowonix Medical, Inc., a medical device company focused on providing advanced, implantable drug delivery solutions and SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty...
- Dec 24, 2020Second milestone payment related to the development of Oral KORSUVA™ follows initial $2.5 million milestone payment received in October
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Dec 18, 2020
WATERTOWN, Mass., Dec. 18, 2020 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative therapeutics to...
- Dec 17, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products based on its proprietary delivery technologies, and a wholly-owned subsidiary of SWK Holdings Corporation...
- Nov 13, 2020Conference Call and Live Audio Webcast Scheduled for Monday, November 16, 2020, at 10:00 a.m. ET
Corporate Highlights Enteris BioPharma, Inc., ("Enteris") a wholly-owned subsidiary of SWK Holdings, recognized $2.5 million in milestone revenue under the license agreement with Cara...
- Nov 11, 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will participate in...
- Oct 29, 2020Third Quarter 2020 Financial Results to be Announced in November 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and...
- Oct 28, 2020
UK-based ostomy specialist Trio Healthcare has secured a multi-million-pound financing from US specialised finance company, SWK Holdings Corporation, as the company targets significant domestic...
- Oct 27, 2020First of multiple anticipated milestone payments related to the development of Oral KORSUVA™
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today announced that its wholly-owned...
- Sep 15, 2020Presentations to Highlight Corporate Achievements and Investment Strategy
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will present at two...
- Sep 15, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Sep 09, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Sep 09, 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its chairman and chief executive officer, Winston Black, will participate in the...
- Aug 31, 2020PDL BioPharma Announces Sale of Kybella®, Zalviso® and Coflex® Royalties to SWK Holdings Corporation
PDL BioPharma, Inc. ("PDL" or the "Company") (Nasdaq: PDLI) announces the signing and closing of a definitive agreement for the sale of three royalty interests for Kybella®, Zalviso®, and...
- Aug 17, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, 2020, at 10:00 a.m. ET
Corporate Highlights Rajiv Khosla, Ph.D. appointed as Chief Executive Officer of Enteris BioPharma Repurchased $1.0 million of common stock during the three-month span ended June 30, 2020 SWK...
- Aug 14, 2020Conference Call and Live Audio Webcast Scheduled for Monday, August 17, at 10:00 a.m. ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced that the Company will host a conference call and live audio webcast on Monday, August 17, 2020,...
- Jun 29, 2020
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today its addition to the broad-market Russell 3000® Index, the Russell 2000® Index and the...
- Jun 23, 2020Presentation Scheduled for June 25, 2020, at 11:30 a.m., ET
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, announced today that Chairman and CEO Winston Black will present via webcast at the Life Sciences...
- Jun 09, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jun 02, 2020
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- May 14, 2020Conference Call and Live Audio Webcast Scheduled for Friday, May 15, 2020, at 10:00 a.m. ET
Corporate Highlights Core specialty finance segment generated an 11.3% adjusted ROIC, and yielding assets increased to $179.2 million, a 15.7% increase in comparison to the quarter ended March 31,...
- May 04, 2020Accomplished Industry Executive Brings Extensive Business Development Experience and Deep Knowledge of Drug Delivery Technology to Enteris
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Mar 30, 2020Transformative 2019 Underscored by Strong Finance Results and Enteris BioPharma Acquisition
Corporate Highlights Core specialty finance segment generated a 12.6% adjusted ROIC and yielding assets increased 4.8% year over year to $175.1 million Closed Enteris Biopharma acquisition SWK...
- Mar 26, 2020SWK Holdings Expects to Report Adjusted Earnings for Fourth Quarter and Year End 2019 of $4.3 to $4.7 million and $21.0 to $21.4 million, respectively
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small and mid-sized commercial-stage companies, today announced its preliminary revenue and...
- Feb 28, 2020Specialty Finance Portfolio Performance Highlights Strong Year, Underscored by Enteris BioPharma Acquisition and NASDAQ Uplisting
SWK Holdings Corporation (Nasdaq: SWKH), a life sciences focused specialty finance company catering to small- and mid-sized commercial-stage companies, today provided an update on the progress and...
- Feb 10, 2020Accomplished Biopharmaceutical and Drug Development Executive to Lead the Expansion of Enteris' External and Internal Development Programs
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 27, 2020Enteris recognized for enhancing positive image of small businesses and service to customers
Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies and a wholly-owned subsidiary of SWK Holdings Corporation...
- Jan 23, 2020Trading begins today, January 23, 2020, under the ticker symbol "SWKH"
SWK Holdings Corporation (Nasdaq: SWKH), a life science focused specialty finance company, today announced that its shares of common stock will begin trading on the Nasdaq Capital Market beginning...
- Jan 21, 2020Trading to begin on January 23, 2020
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, today announced that its shares of common stock have been approved for listing on the...
- Nov 21, 2019Board Realignment Follows SWK's Acquisition of Enteris BioPharma
SWK Holdings Corporation (SWKH.OB) ("SWK" or the "Company"), a life science focused specialty finance company, announced today that Winston Black, Chief Executive Officer of SWK, has been named...
- Nov 18, 2019
Corporate Highlights Acquired Enteris BioPharma, Inc. ("Enteris") a biotechnology company offering innovative formulation solutions utilizing its proprietary oral drug delivery technology,...
- Sep 16, 2019Presentation Scheduled for Today, September 16, 2019, at 4:30 p.m., ET
Dallas, TX, September 16, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, announced that CEO Winston Black, will...
- Sep 06, 2019
Dallas, TX, September 6, 2019 – SWK Holdings Corporation (SWKH.OB) (“SWK” or the “Company”), a life science focused specialty finance company, today announced that its Board of Directors...